Natco Pharma Raises Investment in US Biotech Firm eGenesis to $24.7 Million
Natco Pharma has increased its planned investment in US-based biotechnology firm eGenesis Inc to USD 16.7 million from USD 14 million, with contributions from its Canadian and US subsidiaries. This raises Natco's total investment in eGenesis to USD 24.7 million, including an earlier USD 8 million invested in 2024. eGenesis focuses on developing genetically modified pig organs for transplantation to address organ shortages, with recent successful kidney transplants in humans under FDA oversight.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (60/100). Lens Score 44/100.
Outlets measured: news18, thehindu. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thehindu broke this story on 28 Sept, 01:31 pm. Other outlets followed.
- 1